336 related articles for article (PubMed ID: 34358995)
1. Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication.
Mhatre S; Patravale V
Comput Biol Med; 2021 Sep; 136():104722. PubMed ID: 34358995
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
3. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
4. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Bellanger AP; Albert ND; Lewis RE; Walsh TJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2015 Dec; 59(12):7830-2. PubMed ID: 26392499
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting.
Patel A; Patel K; Patel K; Shah K; Chakrabarti A
Mycoses; 2022 Mar; 65(3):312-316. PubMed ID: 34953080
[TBL] [Abstract][Full Text] [Related]
6. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
Gupta P; Malhotra HS; Saxena P; Singh R; Shukla D; Hasan MS; Verma V; Banerjee G; Puri B; Dandu H
J Investig Med; 2022 Apr; 70(4):914-918. PubMed ID: 35078866
[TBL] [Abstract][Full Text] [Related]
7. Rhizopus Infection in a Preterm Infant: A Novel Use of Posaconazole.
Fatemizadeh R; Rodman E; Demmler-Harrison GJ; Dinu D
Pediatr Infect Dis J; 2020 Apr; 39(4):310-312. PubMed ID: 32084112
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.
Soman R; Chakraborty S; Joe G
Int J Infect Dis; 2022 Jul; 120():177-178. PubMed ID: 35405351
[TBL] [Abstract][Full Text] [Related]
10. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
13. Re: 'Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis' by Manesh et al.
Muthu V; Agarwal R; Chakrabarti A
Clin Microbiol Infect; 2023 Nov; 29(11):1461-1462. PubMed ID: 37473841
[No Abstract] [Full Text] [Related]
14. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
15. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: author's response.
Mukaka M; Manesh A; Varghese GM
Clin Microbiol Infect; 2023 Nov; 29(11):1463-1464. PubMed ID: 37516382
[No Abstract] [Full Text] [Related]
16. In Silico Evaluation of Antifungal Compounds from Marine Sponges against COVID-19-Associated Mucormycosis.
Pokharkar O; Lakshmanan H; Zyryanov G; Tsurkan M
Mar Drugs; 2022 Mar; 20(3):. PubMed ID: 35323514
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Posaconazole against Rhizopus oryzae Infection in Silkworm.
Kurakado S; Matsumoto Y; Sugita T
Med Mycol J; 2021; 62(3):53-57. PubMed ID: 34471035
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole for the treatment of mucormycosis.
Enoch DA; Aliyu SH; Sule O; Lewis SJ; Karas JA
Int J Antimicrob Agents; 2011 Dec; 38(6):465-73. PubMed ID: 21782392
[TBL] [Abstract][Full Text] [Related]
19. Periorbital zygomycosis (mucormycosis) treated with posaconazole.
Rutar T; Cockerham KP
Am J Ophthalmol; 2006 Jul; 142(1):187-188. PubMed ID: 16815283
[TBL] [Abstract][Full Text] [Related]
20. Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.
Goldani LZ; Sugar AM
J Antimicrob Chemother; 1994 Feb; 33(2):369-72. PubMed ID: 8182030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
